Turning Point Therapeutics Inc. (TPTX) Misses Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts TPTX Hot Sheet
Join SI Premium – FREE
Turning Point Therapeutics Inc. (NASDAQ: TPTX) reported Q3 EPS of ($1.34), $0.07 worse than the analyst estimate of ($1.27). Revenue for the quarter came in at $460 thousand.
For earnings history and earnings-related data on Turning Point Therapeutics Inc. (TPTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Argus Upgrades Abercrombie & Fitch (ANF) to Buy
- C1 Fund reports portfolio growth and share repurchase activity
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
